Jinglong Deng

Immunogenicity and safety of the homogenous booster shot of a recombinant fusion protein vaccine (V-01) against COVID-19 in healthy adult participants primed with a two-dose regimen

Jianfeng He, X. Fang, yang-xin fu, 2021, medRxiv.

Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial

Jianfeng He, F. Dèng, W. Guan, 2021, Chinese medical journal.

Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial

Jianfeng He, X. Fang, F. Dèng, 2021, Emerging microbes & infections.

Identifying Potential Candidate Hub Genes and Functionally Enriched Pathways in the Immune Responses to Quadrivalent Inactivated Influenza Vaccines in the Elderly Through Co-Expression Network Analysis

Jiayou Zhang, Xiaoming Yang, Kai Duan, 2020, Frontiers in Immunology.

Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study

Xiaoming Yang, Kai Duan, Wei Chen, 2021, Human vaccines & immunotherapeutics.

Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial

Jianfeng He, X. Fang, F. Dèng, 2021, Emerging Microbes & Infections.